Skip to content
PubMed This is a summary of 59 peer-reviewed journal articles Updated
Pediatric Endocrinology

Laron Syndrome: A Patient Guide

At a Glance

Laron syndrome is a rare genetic condition in which the body cannot respond to growth hormone, causing low levels of the growth factor IGF-1, slowed growth, and severe short stature. Mecasermin may help, but requires meal timing and careful blood sugar monitoring.

Laron syndrome is a rare genetic condition that fundamentally changes how the body uses the signals required for growth. In a typically developing child, the brain releases growth hormone, which acts like a messenger to multiple tissues, notably the liver, instructing it to produce a secondary hormone called IGF-1 (Insulin-like Growth Factor 1). This second hormone is a major pathway that drives the growth of bones and tissues. In classic Laron syndrome, the body often produces plenty of growth hormone, but the “locks” or receptors that are supposed to receive that message are broken or missing. As a result, the body cannot hear the signal to grow, and the production of IGF-1 remains extremely low [1][2].

This disruption in the growth signaling pathway leads to a very distinct pattern of development. While most babies are born at a typical weight and size, their growth begins to slow significantly shortly after birth, eventually resulting in severe short stature. Beyond height, the condition affects how the body manages energy and fat. Children with Laron syndrome often have a higher proportion of body fat and lower muscle mass, and they are prone to periods of low blood sugar, known as hypoglycemia. These metabolic differences mean that the condition is not just about physical height, but about how the body balances fuel and growth throughout life [3][4].

Because the body is “insensitive” to growth hormone, standard growth hormone injections do not work as a treatment. Instead, for children who qualify, a specialist may prescribe a medication called Mecasermin, which bypasses the broken receptors by giving the missing hormone, IGF-1, directly. This specialist-directed medication provides the body with the specific tool it needs to improve linear growth and support bone development. Because IGF-1 is biologically similar to insulin, it can cause blood sugar to drop quickly. Consequently, treatment must be carefully synchronized with meals, and parents must be vigilant in monitoring for signs of low blood sugar according to an individualized action plan to ensure their child’s safety [5][6].

Living with Laron syndrome is a lifelong journey that requires a dedicated team of specialists to monitor both physical growth and metabolic health. This guide is written primarily for parents and caregivers of children navigating this condition. While the diagnosis may feel overwhelming, it marks the beginning of a proactive path toward supporting your child’s unique development. By focusing on safety, consistent treatment, and overall well-being, you can help your child navigate the challenges of the condition [7].

Common questions in this guide

What is Laron syndrome?
Laron syndrome is a rare inherited condition in which the body cannot respond properly to growth hormone. As a result, the body produces very little IGF-1, which supports normal bone and tissue growth, and children may develop severe short stature and other metabolic changes.
Why does standard growth hormone treatment not work for Laron syndrome?
In Laron syndrome, growth hormone may be present, but the receptors that should receive its signal do not work or are missing. Because the signal cannot get through, standard growth hormone injections usually do not correct the underlying problem.
What treatment may help a child with Laron syndrome grow?
For children who qualify, a specialist may prescribe mecasermin, a medication that supplies IGF-1 directly and bypasses the faulty growth hormone receptor. It is used under close medical supervision to support linear growth and bone development.
Why can mecasermin cause low blood sugar?
Mecasermin is biologically similar to insulin and can lower blood sugar quickly. It should be coordinated with meals, and caregivers need an individualized plan for recognizing and responding to low blood sugar.
What signs and body changes can occur with Laron syndrome?
Growth often slows soon after birth, which can lead to severe short stature. Children may also have a higher proportion of body fat, less muscle mass, and episodes of low blood sugar.
How is Laron syndrome evaluated?
Doctors may use laboratory testing and genetic testing to determine whether a growth hormone receptor mutation or another form of growth hormone insensitivity is present. The endocrinology team interprets these results together with the child's growth pattern and clinical findings.
What follow-up does a child with Laron syndrome need?
Laron syndrome requires long-term follow-up with specialists who monitor physical growth and metabolic health. The care team may also track blood sugar and other markers, such as insulin and cholesterol, as the child grows.

Get notified when new evidence is published on Laron syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (7)
  1. 1

    STAT5B deficiency: Impacts on human growth and immunity.

    Hwa V

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2016; (28()):16-20.

    PMID: 26703237
  2. 2

    Laron Syndrome: A Tale of Two Siblings.

    Das N, Tarenia SS, Saha S, et al.

    Journal of the ASEAN Federation of Endocrine Societies 2023; (38(2)):124-127 doi:10.15605/jafes.038.02.22.

    PMID: 38045665
  3. 3

    Laron syndrome in three female siblings with the development of subclinical hypothyroidism and dyslipidemia in one case: first report of a Syrian family.

    Chreitah A, Hijazia K, Doya LJ

    Oxford medical case reports 2021; (2021(9)):omab079 doi:10.1093/omcr/omab079.

    PMID: 34527252
  4. 4

    A 42-Year-Old Woman with Untreated Growth Hormone Insensitivity, Diabetic Retinopathy, and Gene Sequencing Identifies a Variant of Laron Syndrome.

    Castilla-Cortazar I, De Ita JR, García-Magariño M, et al.

    The American journal of case reports 2019; (20()):689-696 doi:10.12659/AJCR.913178.

    PMID: 31086127
  5. 5

    Long-Term Treatment for Laron Syndrome with IGF-1 Injection over 22 Years in Saudi Arabia: A Cohort Study.

    Alashwal AA, Al-Fattani A, Ramzan K, et al.

    Hormone research in paediatrics 2026; (99(4)):469-479 doi:10.1159/000543047.

    PMID: 39657622
  6. 6

    Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry.

    Bang P, Polak M, Bossowski A, et al.

    The Journal of clinical endocrinology and metabolism 2023; (109(1)):46-56 doi:10.1210/clinem/dgad479.

    PMID: 37579214
  7. 7

    Sequential measurements of IGF-I serum concentrations in adolescents with Laron syndrome treated with recombinant human IGF-I (rhIGF-I).

    Breil T, Kneppo C, Bettendorf M, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(8)):895-902 doi:10.1515/jpem-2018-0139.

    PMID: 29995632

This page is for informational purposes only and does not constitute medical advice. Your child's pediatric endocrinologist and care team should guide genetic testing, mecasermin treatment, and blood sugar monitoring.